News Release

Scientists discover a new route to antibiotics using gene editing

Peer-Reviewed Publication

University of Manchester

Scientists have discovered a new chemical process - also known as a biosynthetic pathway - in bacteria which could lead to a new generation of antibiotics being produced and manufactured.

Researchers at The University of Manchester's School of Chemistry say their new pathway includes an enzyme, called a carboxylase, which adds CO2 to a precursor molecule producing a highly unusual antibiotic called malonomycin.

The team says the biosynthetic process used to produce this antibiotic could now possibly lead to the discovery and development of other drugs, helping in the fight against drug-resistant bugs and illnesses in the future.

The work was carried out in collaboration with the University of Cambridge and is being published in Nature Catalysis.

International figures say antibiotic resistance could result in an estimated 10 million deaths every year by 2050, whilst the cost to the global economy could be £66 trillion in lost productivity. Across Europe alone, an estimated 25,000 people already die each year as a result of hospital infections caused by the antibiotic resistant bacteria such as Escherichia coli (E. coli).

Jason Micklefield, Professor of Chemical Biology at the Manchester Institute of Biotechnology, who led the study, said: "The rapid rise of antibiotic-resistant pathogens is one of the foremost global health concerns of modern times.

"Now, using a combination of bioinformatics, gene editing and in vitro experiments, we have discovered a highly unusual biosynthetic pathway to the antibiotic malonomycin. This could pave the way for a new kind of antibiotic production process."

The team originally became interested in malonomycin because it has a highly unusual chemical structure. It possesses potentially useful antimicrobial activity and has already attracted industrial attention. However, despite the interest in this antibiotic, very little was known about the biosynthesis of malonomycin, until now.

The researchers found that CO2 was introduced into the malonomycin structure, by a carboxylase enzyme that has never been characterised in bacteria before. Malonomycin carboxylase is most similar to a carboxylase enzyme in human cells which uses vitamin K to add CO2 to proteins in our bodies, triggering essential physiological responses including blood coagulation.

Clinically important anticoagulant drugs, such as warfarin, work by blocking the function of the human vitamin K-dependent carboxylase. Prof Micklefield added: "We were very surprised to find an antibiotic-producing carboxylase enzyme in bacteria that was similar to the human carboxylase responsible for blood clotting.

"We are now optimistic that our findings might lead to the discovery of new antibiotics and may also provide new ways of making antibiotics which are urgently needed to combat emerging drug-resistant pathogens."

###

Notes to editors

REFERENCE: The paper 'A vitamin K-dependent carboxylase orthologue is involved in antibiotic biosynthesis' is being published Nature Catalysis DOI 10.1038/s41929-018-0178-2

The worked was funded by Biotechnology and Biological Sciences Research Council (BBSRC)

For media enquiries contact Jordan Kenny on 0161 275 8257 or jordan.kenny@manchester.ac.uk

About The University of Manchester

The University of Manchester, a member of the prestigious Russell Group, is one of the UK's largest single-site universities with more than 40,000 students - including more than 10,000 from overseas.It is consistently ranked among the world's elite for graduate employability.

The University is also one of the country's major research institutions, rated fifth in the UK in terms of 'research power' (REF 2014). World-class research is carried out across a diverse range of fields including cancer, advanced materials, global inequalities, energy and industrial biotechnology.

No fewer than 25 Nobel laureates have either worked or studied here.

It is the only UK university to have social responsibility among its core strategic objectives, with staff and students alike dedicated to making a positive difference in communities around the world.

Manchester is ranked 29th in the world in the QS World University Rankings 2018 and 6th in the UK.

Visit http://www.manchester.ac.uk for further information.

Facts and figures: http://www.manchester.ac.uk/discover/facts-figures/

Research Beacons: http://www.manchester.ac.uk/research/beacons/

News and media contacts: http://www.manchester.ac.uk/discover/news/


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.